content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="margin: 0"></P>
  
  
  
  <P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>As filed with the Securities and Exchange Commission on August
  17, 2017</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0; text-align: right"><B>Registration No. 333-</B></P>
  
  <!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 217.05pt; text-indent: 195.05pt"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE
  COMMISSION</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM S-8</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REGISTRATION
  STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNDER</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE SECURITIES ACT OF
  1933</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CELLECT BIOTECHNOLOGY
  LTD.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified
  in its charter)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 49%; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">State of Israel</TD>
      <TD STYLE="width: 2%; font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="width: 49%; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Not applicable</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center">(State or other jurisdiction of <BR>
  incorporation or organization)</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD STYLE="text-align: center">(I.R.S. Employer <BR>
  Identification No.)</TD></TR>
  </TABLE>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">23 Hata&rsquo;as Street,
  Kfar Saba, Israel 44425</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of Principal Executive Offices)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Cellect Biotechnology Ltd. 2014
  Global Incentive Option Scheme</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Full title of the plan)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Vcorp Services, LLC</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>25 Robert Pitt Drive, Suite</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>204
  Monsey, New York</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>10952 (888) 528-2677</B>&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Name, Address and Telephone Number
  of Agent For Service)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Copies of all communications,
  including communications sent to agent for service, should be sent to:</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 50%">
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Ronen Kantor, Esq.</B></P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Giora Gutman, Esq.</B></P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Doron Tikotzky Kantor Gutman Cederboum
          &amp; Co. </B></P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>B.S.R. 4 Tower, 33 Floor</B></P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>7 Metsada Street,</B></P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Bnei Brak 5126112</B></P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Israel</B></P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Tel:&nbsp;(+972) (3) 613-3371&nbsp;</B></P></TD>
      <TD STYLE="width: 50%; text-align: center; vertical-align: bottom">
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Gary Emmanuel, Esq.</B></P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Mark Selinger, Esq.</B></P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>McDermott Will &amp; Emery LLP<BR>
          340 Madison Avenue<BR>
          New York, NY 10173</B></P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Tel: (212) 547-5400&nbsp;</B></P></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth
  company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting
  company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act. (Check one):<BR></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="width: 22%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
  accelerated filer &#9744;</FONT></TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer&nbsp;</FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt"></FONT>&#9744;</TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
  filer&nbsp;</FONT>&#9744;</TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
  reporting company&nbsp;</FONT>&#9744;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Do not check if a smaller reporting company)</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD COLSPAN="3" STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Emerging growth
      company</FONT> &nbsp;&nbsp;&#9746;<FONT STYLE="font: 10pt Wingdings"></FONT> </TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: right"></TD></TR>
  </TABLE>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
  an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant
  has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
  pursuant to Section 7(a)(2)(B) of the Securities Act.&nbsp;</FONT><FONT STYLE="font-family: Wingdings"></FONT>&#9746;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid">Title of Securities to be Registered</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount to be Registered<SUP>(1)</SUP></FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposed maximum offering price per share<SUP>(2)</SUP></FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Proposed maximum aggregate offering price</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Amount of registration fee</TD><TD STYLE="padding-bottom: 1.5pt"><SUP>&nbsp;</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Shares <SUP>(3)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,150,385</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.33</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,039,628</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">120.49</TD><TD STYLE="width: 1%; text-align: left"><SUP>(4)</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Shares <SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.46</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">18,630</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.16</TD><TD STYLE="text-align: left"><SUP>(4)</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Shares <SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6,480</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.75</TD><TD STYLE="text-align: left"><SUP>(4)</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Shares <SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">990,086</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">316,828</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">36.72</TD><TD STYLE="text-align: left"><SUP>(5)</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-weight: bold">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
      <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">4,207,971</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
      <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right"><P STYLE="margin: 0">1,381,566</P>
  
  
  </TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
      <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">160.12</TD><TD STYLE="font-weight: bold; text-align: left"><SUP>&nbsp;</SUP></TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 36pt; text-align: left">(1)</TD><TD STYLE="text-align: justify">Pursuant to Rule 416 under the Securities Act of 1933,
  as amended, this Registration Statement also covers an indeterminate number of additional securities which may be offered and
  issued to prevent dilution resulting from stock splits, stock dividends, recapitalizations or similar transactions.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 36pt; text-align: left">(2)</TD><TD STYLE="text-align: justify">When initially set in New Israeli Shekels (&ldquo;NIS&rdquo;),
  the amount is translated (solely for the purpose of calculating the registration fee) using the rate of NIS 3.586 to US$1.00,
  the representative rate of exchange as of August 11, 2017 as published by the Bank of Israel.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 36pt; text-align: left">(3)</TD><TD STYLE="text-align: justify">American Depository Shares (&ldquo;ADSs&rdquo;), evidenced
  by American Depository Receipts (&ldquo;ADRs&rdquo;), issuable upon deposit of Ordinary Shares, no par value, of Cellect Biotechnology
  Ltd., are registered on a separate registration statement on Form F-6 (File No. 333-212698). Each ADS represents twenty (20) Ordinary
  Shares.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 36pt; text-align: left">(4)</TD><TD STYLE="text-align: justify">Computed in accordance with Rule 457(h) promulgated under
  the Securities Act based on the exercise price of the options underlying the Ordinary Shares.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0%"></TD><TD STYLE="width: 36pt; text-align: left">(5)</TD><TD STYLE="text-align: justify">The fee is based on the number of Ordinary Shares which
  may be issued under the plan this registration statement relates to and is estimated in accordance with paragraphs (c) and (h)
  of Rule 457 under the Securities Act solely for the purpose of calculating the registration fee based upon the average of the
  high and low sales price of an American Depository Share as reported on the Nasdaq Capital Market on August 14, 2017.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">EXPLANATORY NOTE</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">The
  purpose of this Registration Statement is to register 4,207,971 additional Ordinary Shares to be reserved for issuance under the
  Registrant&rsquo;s 2014 Global Incentive Option Scheme. The Ordinary Shares registered hereunder are in addition to 8,163,000 Ordinary
  Shares previously registered on the Company's Form S-8 filed on November 28, 2016 (Commission File No. 333-214817) (the &ldquo;Prior
  Registration Statement&rdquo;). This Registration Statement is submitted in accordance with General Instruction E to Form S-8 regarding
  Registration of Additional Securities. Pursuant to Instruction E, the contents of the Prior Registration Statement is incorporated
  by reference and made part of this Registration Statement, except as amended hereby.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">PART I</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>INFORMATION REQUIRED IN THE SECTION
  10(a) PROSPECTUS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">The
  documents containing the information required in Part I of this Registration Statement have been or will be sent or given to participating
  employees as specified in Rule 428(b)(1) under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), in accordance
  with the rules and regulations of the United States Securities and Exchange Commission (the &ldquo;Commission&rdquo;). Such documents
  are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements
  pursuant to Rule 424 of the Securities Act. These documents and the documents incorporated by reference into this Registration
  Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the
  requirements of Section 10(a) of the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">PART II</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>INFORMATION REQUIRED
  IN THE REGISTRATION STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 50.9pt"><B>Item 3.</B></TD><TD><B>Incorporation of Documents by Reference.</B></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">The
  following additional documents, which have been filed by the Registrant with the Commission are incorporated by reference in and
  made a part of this registration statement, as of their respective dates:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">The Registrant&rsquo;s Annual Report on Form 20-F for
  the year ended December 31, 2016 filed with the Commission on March 23, 2017;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">The Registrant&rsquo;s reports of foreign private issuer on Form 6-K furnished with the
                                                                                    Commission on January 30, 2017, February 6, 2017, February 8, 2017, February 14, 2017, February 17, 2017, February 21, 2017,
                                                                                    March 2, 2017, March 13, 2017, March 16, 2017, March 22, 2017, March
                                                                                    23,                                                                                   2017,
                                                                                    March                                                                                   30,
                                                                                    2017,                                                                                                                April
                                                                                    4,                                                                                   2017,
                                                                                    May                                                                                       3,
                                                                                    2017,                                                                                                             May
                                                                                    4,                                                                                   2017,
                                                                                    May                                                                                                                10,
                                                                                    2017,                                                                                   May
                                                                                    17,                                                                                                              2017,
                                                                                    May                                                                                   30, 2017,
                                                                                    June 12,                                                                                                       2017, June
                                                                                    26,                                                                                   2017,
                                                                                    June 26, 2017 and                                                                                             August
                                                                                    1,                                                                                                2017 (in
                                                                                    each                                                                                                            case, to the
                                                                                    extent                                                                                   expressly
                                                                                    incorporated by                                                                                          reference into the
                                                                                    Company&rsquo;s Registration Statement on Form&nbsp;S-8 (File No.&nbsp;333-214817));</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">The description of the Registrant&rsquo;s American Depositary
  Shares contained in Item 1 of the Registration Statement on Form 8-A (File No. 001-37846) filed with the Commission on July 27,
  2016.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">In
  addition to the foregoing, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of
  the Securities Exchange Act of 1934, as amended, and all reports on Form 6-K subsequently filed
  by the Registrant which state that they are incorporated by reference herein, prior to the filing of a post- effective amendment
  which indicates that all securities offered hereunder have been sold or which deregisters all securities then remaining unsold,
  shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such documents and reports.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">Any
  statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified
  or superseded for purposes of this registration statement to the extent that a statement herein, or in any subsequently filed document
  which also is or is deemed to be incorporated by reference, modifies or supersedes such statement. Any statement so modified or
  superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Item 8. Exhibits.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.75in; text-align: justify"><FONT STYLE="font-weight: normal">Reference
  is made to the Exhibit Index on the page immediately preceding the exhibits for a list of exhibits filed as part of this Registration
  Statement, which Exhibit Index is incorporated herein by reference.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  
  <!-- Field: Page; Sequence: 3 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SIGNATURES</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">Pursuant to the requirements
  of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
  for filing on Form S-8 and has duly caused this Registration Statement on Form S-8 to be signed on its behalf by the undersigned,
  thereunto duly authorized, in the City of Kfar Saba, State of Israel, on the 17<SUP>th</SUP> day of August, 2017.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="font-weight: bold">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-weight: bold">CELLECT BIOTECHNOLOGY LTD.</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="font-weight: bold; width: 60%">&nbsp;</TD>
      <TD STYLE="font-weight: bold; width: 4%">&nbsp;</TD>
      <TD STYLE="font-weight: bold; width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>By:</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Shai Yarkoni</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>Name: Dr. Shai Yarkoni</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>Title: Chief Executive Officer</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 154.45pt"><A NAME="c_001"></A>POWER OF ATTORNEY AND SIGNATURES</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We, the
  undersigned officers and directors of Cellect Biotechnology Ltd., hereby severally constitute and appoint Dr. Shai Yarkoni and
  Eyal Leibovitz, and each of them individually, our true and lawful attorney to sign for us and in our names in the capacities indicated
  below any and all amendments or supplements, including any post-effective amendments, to this registration statement on Form S-8
  and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission,
  granting unto said attorney full power and authority to do and perform each and every act and thing requisite or necessary to be
  done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming
  our signatures to said amendments to this registration statement signed by our said attorney and all else that said attorney may
  lawfully do and cause to be done by virtue hereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.55pt 0pt 10.9pt; text-align: justify; text-indent: 16.1pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Pursuant to the requirements
  of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and
  on the dates indicated:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.1pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 30%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</FONT></TD>
      <TD STYLE="width: 2%">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</FONT></TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 20%; border-bottom: black 1.5pt solid; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
      <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Shai Yarkoni</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Shai Yarkoni</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal executive officer)</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 17, 2017</FONT></TD></TR>
  <TR>
      <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding-left: 9.9pt; text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR>
      <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Eyal Leibovitz</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eyal Leibovitz</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal financial officer and principal accounting officer)</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 17, 2017</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="padding-left: 9.9pt; text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Kasbian Nuriel Chirich</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kasbian Nuriel Chirich</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 17, 2017</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="padding-left: 9.9pt; text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Abraham Nahmias</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abraham Nahmias</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 17, 2017</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="padding-left: 9.9pt; text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ruth Ben Yakar</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Ruth Ben Yakar</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 17, 2017</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="padding-left: 9.9pt; text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Yuval Berman</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yuval Berman</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 17, 2017</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="padding-left: 9.9pt; text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ David Grossman</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Grossman</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 17, 2017</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Michael Berelowitz</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Berelowitz</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 17, 2017</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  </TABLE>
  
  <!-- Field: Page; Sequence: 4 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE
  UNITED STATES</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Pursuant to the Securities
  Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Cellect Biotechnology Ltd.
  has signed this registration statement in the city of Monsey, the State of New York, on August 17, 2017.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="font-weight: bold">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-weight: bold">VCORP SERVICES, LLC</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 60%">&nbsp;</TD>
      <TD STYLE="width: 4%">&nbsp;</TD>
      <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>By:</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid"> /s/ Isaac Muller</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>Name: Isaac Muller</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>Title: Authorized Representative</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 5 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>EXHIBIT INDEX</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.85pt 0pt 82.9pt; text-indent: -73.9pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 9%; padding-right: 12.85pt; text-align: justify; vertical-align: bottom; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT><BR>
  <FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD>
      <TD STYLE="width: 2%; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
      <TD STYLE="width: 89%; padding-right: 12.85pt; text-align: center; vertical-align: bottom; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 12.85pt; text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="padding-right: 12.85pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="padding-right: 12.85pt; text-align: justify">4.1</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1671502/000114420416112021/v443727_ex3-1.htm">Articles&nbsp;of Association&nbsp;of Cellect Biotechnology Ltd. (unofficial English translation from Hebrew original) (1)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="padding-top: 0.05pt; text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="padding-top: 0.05pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="padding-right: 12.85pt; text-align: justify">4.2</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1671502/000114420416114170/v444862_ex3-2.htm">Certificate of Name Change of Cellect Biotechnology Ltd. (unofficial English translation from Hebrew original) (2)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="padding-right: 12.85pt; text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="padding-right: 12.85pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="padding-right: 12.85pt; text-align: justify">4.3</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1671502/000114420416114563/v444964_ex4-1.htm">Form of Deposit Agreement among the Registrant, the Bank of New York Mellon, as Depositary, and all Owners and Holders from time to time of American Depositary Shares issued hereunder (3)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="padding-right: 12.85pt; text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="padding-right: 12.85pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="padding-right: 12.85pt; text-align: justify">5.1</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="fs82017ex5i_cellectbiotech.htm">Opinion of Doron Tikotzky Kantor Gutman Cederboum &amp; Co., Israeli counsel to Cellect Biotechnology Ltd. (including consent)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="padding-right: 12.85pt; text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="padding-right: 12.85pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="padding-right: 12.85pt; text-align: justify">23.1</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="fs82017ex23i_cellectbiotech.htm">Consent of Kost Forer Gabbay &amp; Kasierer, Certified Public Accountant (Isr.), a member of Ernst &amp; Young Israel</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="padding-right: 12.85pt; text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="padding-right: 12.85pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="padding-right: 12.85pt; text-align: justify">23.2</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="fs82017ex5i_cellectbiotech.htm">Consent of Doron Tikotzky Kantor Gutman Cederboum &amp; Co. (included in the opinion filed as Exhibit 5.1 to this Registration Statement)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="padding-top: 0.05pt; text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="padding-top: 0.05pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="padding-right: 12.85pt; text-align: justify">24.1</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="#c_001">Power of Attorney (included on signature page)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="padding-top: 0.55pt; text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="padding-top: 0.55pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="padding-right: 12.85pt; text-align: justify">99.1</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1671502/000114420416112021/v443727_ex10-6.htm">Cellect Biotechnology Ltd. 2014 Global Incentive Option Scheme (4)</A></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 4%">(1)</TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 95%; text-align: justify">Previously filed as Exhibit 3.1 to the Registrant&rsquo;s registration statement on Form F-1 filed on July 7, 2016, and incorporated herein by reference.</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>(2)</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">Previously filed as Exhibit 3.2 to the Registrant&rsquo;s registration statement on Form F-1 filed on July 25, 2016, and incorporated herein by reference.</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>(3)</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">Previously filed as Exhibit 4.1 to the Registrant&rsquo;s registration statement on Form F-1 filed on July 26, 2016, and incorporated herein by reference.</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>(4)</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">Previously filed as Exhibit 10.6 to the Registrant&rsquo;s registration statement on Form F-1 filed on July 7, 2016, and incorporated herein by reference.</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  
  
  <P STYLE="margin: 0">&nbsp;</P>
  
  <P STYLE="margin: 0"></P>
  
  <!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="margin: 0">&nbsp;</P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "fs82017_cellectbiotech.htm", "description": "INITIAL REGISTRATION STATEMENT FOR SECURITIES TO BE OFFERED TO EMPLOYEES.", "secsgml_size_bytes": 59234}]
metadata_filer: {"company-data": {"conformed-name": "Cellect Biotechnology Ltd.", "cik": "0001671502", "assigned-sic": "3841", "irs-number": "000000000"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-220015", "film-number": "171039002"}, "business-address": {"street1": "23 HATA'AS STREET", "city": "KFAR SABA", "state": "L3", "zip": "44425", "phone": "97299741444"}, "mail-address": {"street1": "23 HATA'AS STREET", "city": "KFAR SABA", "state": "L3", "zip": "44425"}, "former-company": {"former-conformed-name": "Cellect Biomed Ltd.", "date-changed": "20160406"}}
text: As filed with the Securities and Exchange Commission on August
  17, 2017
  Registration No. 333-
  UNITED STATES
  SECURITIES AND EXCHANGE
  COMMISSION
  WASHINGTON, D.C. 20549
  FORM S-8
  REGISTRATION
  STATEMENT
  UNDER
  THE SECURITIES ACT OF
  1933
  CELLECT BIOTECHNOLOGY
  LTD.
  (Exact name of registrant as specified
  in its charter)
  State of Israel
  Not applicable
  (State or other jurisdiction of
  incorporation or organization)
  (I.R.S. Employer
  Identification No.)
  23 Hata'as Street,
  Kfar Saba, Israel 44425
  (Address of Principal Executive Offices)
  Cellect Biotechnology Ltd. 2014
  Global Incentive Option Scheme
  (Full title of the plan)
  Vcorp Services, LLC
  25 Robert Pitt Drive, Suite
  204
  Monsey, New York
  10952 (888) 528-2677
  (Name, Address and Telephone Number
  of Agent For Service)
  Copies of all communications,
  including communications sent to agent for service, should be sent to:
  Ronen Kantor, Esq.
  Giora Gutman, Esq.
  Doron Tikotzky Kantor Gutman Cederboum
          & Co.
  B.S.R. 4 Tower, 33 Floor
  7 Metsada Street,
  Bnei Brak 5126112
  Israel
  Tel: (+972) (3) 613-3371
  Gary Emmanuel, Esq.
  Mark Selinger, Esq.
  McDermott Will & Emery LLP
  340 Madison Avenue
  New York, NY 10173
  Tel: (212) 547-5400
  Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth
  company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting
  company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):
  Large
  accelerated filer ☐
  Accelerated filer
  ☐
  Non-accelerated
  filer
  ☐
  Smaller
  reporting company
  ☐
  (Do not check if a smaller reporting company)
  Emerging growth
      company
  ☒
  If
  an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant
  has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
  pursuant to Section 7(a)(2)(B) of the Securities Act.
  ☒
  CALCULATION OF REGISTRATION FEE
  Title of Securities to be Registered
  Amount to be Registered
  (1)
  Proposed maximum offering price per share
  (2)
  Proposed maximum aggregate offering price
  Amount of registration fee
  Ordinary Shares
  (3)
  3,150,385
  $
  0.33
  $
  1,039,628
  $
  120.49
  (4)
  Ordinary Shares
  (3)
  40,500
  $
  0.46
  $
  18,630
  $
  2.16
  (4)
  Ordinary Shares
  (3)
  27,000
  $
  0.24
  $
  6,480
  $
  0.75
  (4)
  Ordinary Shares
  (3)
  990,086
  $
  0.32
  $
  316,828
  $
  36.72
  (5)
  Total
  4,207,971
  $
  1,381,566
  $
  160.12
  (1)
  Pursuant to Rule 416 under the Securities Act of 1933,
  as amended, this Registration Statement also covers an indeterminate number of additional securities which may be offered and
  issued to prevent dilution resulting from stock splits, stock dividends, recapitalizations or similar transactions.
  (2)
  When initially set in New Israeli Shekels ("NIS"),
  the amount is translated (solely for the purpose of calculating the registration fee) using the rate of NIS 3.586 to US$1.00,
  the representative rate of exchange as of August 11, 2017 as published by the Bank of Israel.
  (3)
  American Depository Shares ("ADSs"), evidenced
  by American Depository Receipts ("ADRs"), issuable upon deposit of Ordinary Shares, no par value, of Cellect Biotechnology
  Ltd., are registered on a separate registration statement on Form F-6 (File No. 333-212698). Each ADS represents twenty (20) Ordinary
  Shares.
  (4)
  Computed in accordance with Rule 457(h) promulgated under
  the Securities Act based on the exercise price of the options underlying the Ordinary Shares.
  (5)
  The fee is based on the number of Ordinary Shares which
  may be issued under the plan this registration statement relates to and is estimated in accordance with paragraphs (c) and (h)
  of Rule 457 under the Securities Act solely for the purpose of calculating the registration fee based upon the average of the
  high and low sales price of an American Depository Share as reported on the Nasdaq Capital Market on August 14, 2017.
  EXPLANATORY NOTE
  The
  purpose of this Registration Statement is to register 4,207,971 additional Ordinary Shares to be reserved for issuance under the
  Registrant's 2014 Global Incentive Option Scheme. The Ordinary Shares registered hereunder are in addition to 8,163,000 Ordinary
  Shares previously registered on the Company's Form S-8 filed on November 28, 2016 (Commission File No. 333-214817) (the "Prior
  Registration Statement"). This Registration Statement is submitted in accordance with General Instruction E to Form S-8 regarding
  Registration of Additional Securities. Pursuant to Instruction E, the contents of the Prior Registration Statement is incorporated
  by reference and made part of this Registration Statement, except as amended hereby.
  PART I
  INFORMATION REQUIRED IN THE SECTION
  10(a) PROSPECTUS
  The
  documents containing the information required in Part I of this Registration Statement have been or will be sent or given to participating
  employees as specified in Rule 428(b)(1) under the Securities Act of 1933, as amended (the "Securities Act"), in accordance
  with the rules and regulations of the United States Securities and Exchange Commission (the "Commission"). Such documents
  are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements
  pursuant to Rule 424 of the Securities Act. These documents and the documents incorporated by reference into this Registration
  Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the
  requirements of Section 10(a) of the Securities Act.
  PART II
  INFORMATION REQUIRED
  IN THE REGISTRATION STATEMENT
  Item 3.
  Incorporation of Documents by Reference.
  The
  following additional documents, which have been filed by the Registrant with the Commission are incorporated by reference in and
  made a part of this registration statement, as of their respective dates:
  (a)
  The Registrant's Annual Report on Form 20-F for
  the year ended December 31, 2016 filed with the Commission on March 23, 2017;
  (b)
  The Registrant's reports of foreign private issuer on Form 6-K furnished with the
                                                                                    Commission on January 30, 2017, February 6, 2017, February 8, 2017, February 14, 2017, February 17, 2017, February 21, 2017,
                                                                                    March 2, 2017, March 13, 2017, March 16, 2017, March 22, 2017, March
                                                                                    23,                                                                                   2017,
                                                                                    March                                                                                   30,
                                                                                    2017,                                                                                                                April
                                                                                    4,                                                                                   2017,
                                                                                    May                                                                                       3,
                                                                                    2017,                                                                                                             May
                                                                                    4,                                                                                   2017,
                                                                                    May                                                                                                                10,
                                                                                    2017,                                                                                   May
                                                                                    17,                                                                                                              2017,
                                                                                    May                                                                                   30, 2017,
                                                                                    June 12,                                                                                                       2017, June
                                                                                    26,                                                                                   2017,
                                                                                    June 26, 2017 and                                                                                             August
                                                                                    1,                                                                                                2017 (in
                                                                                    each                                                                                                            case, to the
                                                                                    extent                                                                                   expressly
                                                                                    incorporated by                                                                                          reference into the
                                                                                    Company's Registration Statement on Form S-8 (File No. 333-214817));
  (c)
  The description of the Registrant's American Depositary
  Shares contained in Item 1 of the Registration Statement on Form 8-A (File No. 001-37846) filed with the Commission on July 27,
  2016.
  In
  addition to the foregoing, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of
  the Securities Exchange Act of 1934, as amended, and all reports on Form 6-K subsequently filed
  by the Registrant which state that they are incorporated by reference herein, prior to the filing of a post- effective amendment
  which indicates that all securities offered hereunder have been sold or which deregisters all securities then remaining unsold,
  shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such documents and reports.
  Any
  statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified
  or superseded for purposes of this registration statement to the extent that a statement herein, or in any subsequently filed document
  which also is or is deemed to be incorporated by reference, modifies or supersedes such statement. Any statement so modified or
  superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.
  Item 8. Exhibits.
  Reference
  is made to the Exhibit Index on the page immediately preceding the exhibits for a list of exhibits filed as part of this Registration
  Statement, which Exhibit Index is incorporated herein by reference.
  SIGNATURES
  Pursuant to the requirements
  of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
  for filing on Form S-8 and has duly caused this Registration Statement on Form S-8 to be signed on its behalf by the undersigned,
  thereunto duly authorized, in the City of Kfar Saba, State of Israel, on the 17
  th
  day of August, 2017.
  CELLECT BIOTECHNOLOGY LTD.
  By:
  /s/ Shai Yarkoni
  Name: Dr. Shai Yarkoni
  Title: Chief Executive Officer
  POWER OF ATTORNEY AND SIGNATURES
  We, the
  undersigned officers and directors of Cellect Biotechnology Ltd., hereby severally constitute and appoint Dr. Shai Yarkoni and
  Eyal Leibovitz, and each of them individually, our true and lawful attorney to sign for us and in our names in the capacities indicated
  below any and all amendments or supplements, including any post-effective amendments, to this registration statement on Form S-8
  and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission,
  granting unto said attorney full power and authority to do and perform each and every act and thing requisite or necessary to be
  done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming
  our signatures to said amendments to this registration statement signed by our said attorney and all else that said attorney may
  lawfully do and cause to be done by virtue hereof.
  Pursuant to the requirements
  of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and
  on the dates indicated:
  Name
  Title
  Date
  /s/ Shai Yarkoni
  Chief Executive Officer and Director
  Dr. Shai Yarkoni
  (principal executive officer)
  August 17, 2017
  /s/ Eyal Leibovitz
  Chief Financial Officer
  Eyal Leibovitz
  (principal financial officer and principal accounting officer)
  August 17, 2017
  /s/ Kasbian Nuriel Chirich
  Chairman of the Board
  Kasbian Nuriel Chirich
  August 17, 2017
  /s/ Abraham Nahmias
  Director
  Abraham Nahmias
  August 17, 2017
  /s/ Ruth Ben Yakar
  Director
  Dr. Ruth Ben Yakar
  August 17, 2017
  /s/ Yuval Berman
  Director
  Yuval Berman
  August 17, 2017
  /s/ David Grossman
  Director
  David Grossman
  August 17, 2017
  /s/ Michael Berelowitz
  Director
  Michael Berelowitz
  August 17, 2017
  SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE
  UNITED STATES
  Pursuant to the Securities
  Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Cellect Biotechnology Ltd.
  has signed this registration statement in the city of Monsey, the State of New York, on August 17, 2017.
  VCORP SERVICES, LLC
  By:
  /s/ Isaac Muller
  Name: Isaac Muller
  Title: Authorized Representative
  EXHIBIT INDEX
  Exhibit
  Number
  Description
  4.1
  Articles of Association of Cellect Biotechnology Ltd. (unofficial English translation from Hebrew original) (1)
  4.2
  Certificate of Name Change of Cellect Biotechnology Ltd. (unofficial English translation from Hebrew original) (2)
  4.3
  Form of Deposit Agreement among the Registrant, the Bank of New York Mellon, as Depositary, and all Owners and Holders from time to time of American Depositary Shares issued hereunder (3)
  5.1
  Opinion of Doron Tikotzky Kantor Gutman Cederboum & Co., Israeli counsel to Cellect Biotechnology Ltd. (including consent)
  23.1
  Consent of Kost Forer Gabbay & Kasierer, Certified Public Accountant (Isr.), a member of Ernst & Young Israel
  23.2
  Consent of Doron Tikotzky Kantor Gutman Cederboum & Co. (included in the opinion filed as Exhibit 5.1 to this Registration Statement)
  24.1
  Power of Attorney (included on signature page)
  99.1
  Cellect Biotechnology Ltd. 2014 Global Incentive Option Scheme (4)
  (1)
  Previously filed as Exhibit 3.1 to the Registrant's registration statement on Form F-1 filed on July 7, 2016, and incorporated herein by reference.
  (2)
  Previously filed as Exhibit 3.2 to the Registrant's registration statement on Form F-1 filed on July 25, 2016, and incorporated herein by reference.
  (3)
  Previously filed as Exhibit 4.1 to the Registrant's registration statement on Form F-1 filed on July 26, 2016, and incorporated herein by reference.
  (4)
  Previously filed as Exhibit 10.6 to the Registrant's registration statement on Form F-1 filed on July 7, 2016, and incorporated herein by reference.